Section Arrow
CLDI.NYSE-M
- Calidi Biotherapeutics
Quotes are at least 15-min delayed:2026/06/23 07:04 EDT
Pre Market
Last
 0.1537
-0.0063 (-3.94%)
Bid
0.1516
Ask
0.1541
High 0.1588 
Low 0.1505 
Volume 275.66K 
Regular Hours (Closed)
Last
 0.16
-0.0089 (-5.27%)
Day High 
0.1629 
Prev. Close
0.1689 
1-M High
0.1975 
Volume 
2.56M 
Bid
0.1516
Ask
0.1541
Day Low
0.156 
Open
0.162 
1-M Low
0.1201 
Market Cap 
3.26M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.17 
20-SMA 0.17 
50-SMA 0.2 
52-W High 19.2 
52-W Low 0.1201 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-4.17/-8.80
Enterprise Value
4.31M
Balance Sheet
Book Value Per Share
0.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0192+0.0092+92.00%-- 
Pre Market 0.025 +0.0058 +30.21%
AZTRAzitra0.23+0.0583+33.95%-- 
Pre Market 0.211 -0.019 -8.26%
CDTCDT Equity Inc.1.5+0.48+47.06%-- 
Pre Market 1.25 -0.25 -16.67%
APGEApogee Therapeutics132.55+42.17+46.66%-- 
Pre Market 132.53 -0.02 -0.02%
ENTXEntera Bio Ltd1.48+0.27+22.31%-- 
Pre Market 1.29 -0.19 -12.84%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed HighGrade Glioma.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.